Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib vs Liposomal Doxorubicin in BRCA-mutated Ovarian Cancer
NCT00628251Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Started Jul 2008; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00628251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00628251.